Reimbursement

Patients' W.A.I.T. Indicator - Report 2010

The latest edition shows that, depending on the patients' country of residence, doctors would be able to prescribe between 39% and 86% of the new medicines with a valid EU marketing authorisation granted between 1 January 2007 and 31 December 2009. For those new medicines that doctors can prescribe under the national healthcare provisions, average time elapsing between the date of EU market authorisation and the "accessibility" date in 14 European countries will vary from 88 to 392 days.

Transparency Directive (COM (2012)0084) - (29 May 2012)

The Commission proposal for a revised Transparency Directive (“the Proposal”) is an important and necessary step towards more efficient decision-making by member states in pricing and reimbursement (P&R) of medicines. At a time when countries across the EU are seeking improved management of their healthcare systems, it is essential that the procedural aspects of P&R decision-making are brought towards similar standards of quality and efficiency.

Joint Healthcare Industry Paper: The value of industry involvement in HTA (08/12/2011)

What is the aim of HTA?
According to the EUnetHTA definition1, health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective health policies that are patient focused and seek to achieve best value.
 
Subscribe to RSS - Reimbursement